Status:
RECRUITING
Mechanisms for Activation of Beige Adipose Tissue in Humans
Lead Sponsor:
Philip Kern
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
PreDiabetes
Eligibility:
All Genders
35-65 years
Phase:
PHASE2
Brief Summary
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose ...
Detailed Description
Among the many survival adaptations developed by mammals is a defense against the cold and hypothermia; one of these adaptations is the ability to uncouple oxidative phosphorylation and generate heat,...
Eligibility Criteria
Inclusion
- BMI 27-45
- prediabetes (A1c 5.7-6.4)
- impaired fasting glucose or impaired glucose tolerance
Exclusion
- diabetes
- chronic use of anti-diabetic medication
- acute or chronic inflammatory condition
- unstable medical condition
- cancer
- renal insufficiency
- any contraindication for Mirabegron
- BMI \>45
Key Trial Info
Start Date :
December 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04666636
Start Date
December 7 2020
End Date
December 1 2026
Last Update
December 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky
Lexington, Kentucky, United States, 40536